JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $375

JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $400 to $375.